JP2024023349A5 - - Google Patents

Download PDF

Info

Publication number
JP2024023349A5
JP2024023349A5 JP2023196825A JP2023196825A JP2024023349A5 JP 2024023349 A5 JP2024023349 A5 JP 2024023349A5 JP 2023196825 A JP2023196825 A JP 2023196825A JP 2023196825 A JP2023196825 A JP 2023196825A JP 2024023349 A5 JP2024023349 A5 JP 2024023349A5
Authority
JP
Japan
Prior art keywords
liposome
composition
compound
peg
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023196825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024023349A (ja
Filing date
Publication date
Priority claimed from JP2018554659A external-priority patent/JP6918829B2/ja
Application filed filed Critical
Publication of JP2024023349A publication Critical patent/JP2024023349A/ja
Publication of JP2024023349A5 publication Critical patent/JP2024023349A5/ja
Priority to JP2025282870A priority Critical patent/JP2026053650A/ja
Pending legal-status Critical Current

Links

JP2023196825A 2016-01-11 2023-11-20 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害 Pending JP2024023349A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025282870A JP2026053650A (ja) 2016-01-11 2025-12-25 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662277262P 2016-01-11 2016-01-11
US62/277,262 2016-01-11
US201662420258P 2016-11-10 2016-11-10
US62/420,258 2016-11-10
US201762444172P 2017-01-09 2017-01-09
US62/444,172 2017-01-09
JP2018554659A JP6918829B2 (ja) 2016-01-11 2017-01-11 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2021120731A JP7439023B2 (ja) 2016-01-11 2021-07-21 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021120731A Division JP7439023B2 (ja) 2016-01-11 2021-07-21 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025282870A Division JP2026053650A (ja) 2016-01-11 2025-12-25 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Publications (2)

Publication Number Publication Date
JP2024023349A JP2024023349A (ja) 2024-02-21
JP2024023349A5 true JP2024023349A5 (cg-RX-API-DMAC7.html) 2024-05-24

Family

ID=59311885

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018554659A Active JP6918829B2 (ja) 2016-01-11 2017-01-11 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2021120731A Active JP7439023B2 (ja) 2016-01-11 2021-07-21 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2023196825A Pending JP2024023349A (ja) 2016-01-11 2023-11-20 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2025282870A Pending JP2026053650A (ja) 2016-01-11 2025-12-25 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018554659A Active JP6918829B2 (ja) 2016-01-11 2017-01-11 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2021120731A Active JP7439023B2 (ja) 2016-01-11 2021-07-21 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025282870A Pending JP2026053650A (ja) 2016-01-11 2025-12-25 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Country Status (17)

Country Link
US (5) US10570119B2 (cg-RX-API-DMAC7.html)
EP (3) EP3936153B1 (cg-RX-API-DMAC7.html)
JP (4) JP6918829B2 (cg-RX-API-DMAC7.html)
KR (2) KR102461219B1 (cg-RX-API-DMAC7.html)
CN (2) CN116211803B (cg-RX-API-DMAC7.html)
AU (3) AU2017207299B2 (cg-RX-API-DMAC7.html)
DK (2) DK3402532T3 (cg-RX-API-DMAC7.html)
ES (2) ES2997263T3 (cg-RX-API-DMAC7.html)
FI (1) FI3936153T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241512T1 (cg-RX-API-DMAC7.html)
IL (2) IL260487B2 (cg-RX-API-DMAC7.html)
MA (1) MA43870A (cg-RX-API-DMAC7.html)
MX (1) MX2018008507A (cg-RX-API-DMAC7.html)
PL (1) PL3402532T3 (cg-RX-API-DMAC7.html)
PT (1) PT3936153T (cg-RX-API-DMAC7.html)
SI (1) SI3936153T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017123588A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
TWI755629B (zh) * 2018-09-13 2022-02-21 台灣微脂體股份有限公司 含鎮靜藥物之緩釋藥物組合物及其用途
EP3866764A4 (en) * 2018-10-17 2022-07-13 Taiwan Liposome Company, Ltd. DELAYED RELEASE PHARMACEUTICAL COMPOSITIONS WITH AN IMMUNOMODULATING AGENT AND USES THEREOF
US20230190752A1 (en) * 2020-05-07 2023-06-22 Washington University Compositions and methods for predicting therapeutic outcome
AU2021292747A1 (en) 2020-06-18 2023-02-23 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
EP4210692A4 (en) * 2020-09-14 2024-10-02 Zhuhai Beihai Biotech Co., Ltd. Formulations of cabazitaxel
AU2021360636A1 (en) 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
WO2025019346A2 (en) * 2023-07-14 2025-01-23 Celator Pharmaceuticals, Inc. Methods of use of a liposomal composition comprising an atr inhibitor
WO2025019344A2 (en) * 2023-07-14 2025-01-23 Jazz Pharmaceuticals, Inc. Combinations comprising an atr inhibitor and a parp inhibitor and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990610A (en) 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DE602004015429D1 (de) 2003-03-11 2008-09-11 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
GB0411401D0 (en) 2004-05-21 2004-06-23 Tissuomics Ltd Penetrating radiation measurements
EP1778648A2 (en) 2004-08-19 2007-05-02 ICOS Corporation Compounds useful for inhibiting chk1
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
EP2153820A4 (en) 2007-05-14 2013-12-25 Konica Minolta Holdings Inc LIPOSOM AND METHOD FOR THE PRODUCTION OF LIPOSOMY
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
JP5951994B2 (ja) 2008-12-19 2016-07-13 イマージョン コーポレーションImmersion Corporation 対話型ペインティングゲーム及び関連するコントローラ
TW201028410A (en) * 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
BR112012005343A2 (pt) 2009-09-10 2016-03-22 Novartis Ag sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼ阻害剤として有用な化合物
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
JP2013529643A (ja) 2010-06-23 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピロロピラジン誘導体
CN102485213A (zh) * 2010-12-01 2012-06-06 沈阳药科大学 伊立替康脂质体及其制备方法
CN102485212B (zh) * 2010-12-01 2014-04-09 沈阳药科大学 苹果酸舒尼替尼脂质体及其制备方法
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (cg-RX-API-DMAC7.html) * 2011-09-30 2015-08-21 Vertex Pharma
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) * 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) * 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en) * 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
EP3164420A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)

Similar Documents

Publication Publication Date Title
US8956646B2 (en) Zwitterionic lipids
US6586559B2 (en) Polyamide oligomers
JP2005504749A5 (cg-RX-API-DMAC7.html)
JP2021522163A5 (cg-RX-API-DMAC7.html)
JP2001527052A5 (cg-RX-API-DMAC7.html)
JP2001527052A (ja) ポリアミドオリゴマー
JP2004511572A (ja) 標的化送達のための脂質製剤
JP2020519625A5 (cg-RX-API-DMAC7.html)
PT742789E (pt) Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao
JPH04501117A (ja) リポソーム類
JP2024540101A5 (cg-RX-API-DMAC7.html)
PT97500B (pt) Processo de producao de lipossomas e de preparados farmaceuticos contendo aqueles lipossomas
BR112014022847B1 (pt) Lipídios aminoácidos, composição vesicular, e kit
JP2026503201A5 (cg-RX-API-DMAC7.html)
IL313681A (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
JP2005505521A5 (cg-RX-API-DMAC7.html)
JP4723097B2 (ja) サイトフェクチン二量体およびその使用方法
CN1088582C (zh) 能治疗多种疾病具有层状类脂组分的类脂基载体、其组合物及其应用
US20040213835A1 (en) Method to reduce liposome-induced complement activation
JP2019508473A (ja) 標的ドセタキセル産生ナノリポソーム組成物を用いたエフリン受容体A2(EphA2)陽性癌の治療
JP2003528908A (ja) Dおよびlエーテル脂質立体異性体およびリポソーム
BRPI0717800A2 (pt) COMPOSIÇÃO DE LIPOSSOMAS SENSÍVEIS AO pH
JPWO2023054241A5 (cg-RX-API-DMAC7.html)
US7008614B2 (en) Liposome containing hydrophobic iodine compound and X-ray contrast medium for radiograph comprising the liposome
KR100829595B1 (ko) 당이 결합된 인지질로 수식된 리포솜 및 이의 제조방법